249 related articles for article (PubMed ID: 24957522)
1. Bayesian methods for the design and interpretation of clinical trials in very rare diseases.
Hampson LV; Whitehead J; Eleftheriou D; Brogan P
Stat Med; 2014 Oct; 33(24):4186-201. PubMed ID: 24957522
[TBL] [Abstract][Full Text] [Related]
2. Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa.
Hampson LV; Whitehead J; Eleftheriou D; Tudur-Smith C; Jones R; Jayne D; Hickey H; Beresford MW; Bracaglia C; Caldas A; Cimaz R; Dehoorne J; Dolezalova P; Friswell M; Jelusic M; Marks SD; Martin N; McMahon AM; Peitz J; van Royen-Kerkhof A; Soylemezoglu O; Brogan PA
PLoS One; 2015; 10(3):e0120981. PubMed ID: 25822991
[TBL] [Abstract][Full Text] [Related]
3. Remote, real-time expert elicitation to determine the prior probability distribution for Bayesian sample size determination in international randomised controlled trials: Bronchiolitis in Infants Placebo Versus Epinephrine and Dexamethasone (BIPED) study.
Lan J; Plint AC; Dalziel SR; Klassen TP; Offringa M; Heath A;
Trials; 2022 Apr; 23(1):279. PubMed ID: 35410375
[TBL] [Abstract][Full Text] [Related]
4. Improving efficiency in the stepped-wedge trial design via Bayesian modeling with an informative prior for the time effects.
Zhan D; Ouyang Y; Xu L; Wong H
Clin Trials; 2021 Jun; 18(3):295-302. PubMed ID: 33813906
[TBL] [Abstract][Full Text] [Related]
5. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
6. Optimal sample size determination for single-arm trials in pediatric and rare populations with Bayesian borrowing.
Ji Z; Lin J; Lin J
J Biopharm Stat; 2022 Jul; 32(4):529-546. PubMed ID: 35604836
[TBL] [Abstract][Full Text] [Related]
7. Bayesian approach to noninferiority trials for proportions.
Gamalo MA; Wu R; Tiwari RC
J Biopharm Stat; 2011 Sep; 21(5):902-19. PubMed ID: 21830922
[TBL] [Abstract][Full Text] [Related]
8. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
Lewis RJ; Lipsky AM; Berry DA
Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
[TBL] [Abstract][Full Text] [Related]
9. Analysis of phase II methodologies for single-arm clinical trials with multiple endpoints in rare cancers: An example in Ewing's sarcoma.
Dutton P; Love SB; Billingham L; Hassan AB
Stat Methods Med Res; 2018 May; 27(5):1451-1463. PubMed ID: 27587590
[TBL] [Abstract][Full Text] [Related]
10. Utility of Bayesian Single-Arm Design in New Drug Application for Rare Cancers in Japan: A Case Study of Phase 2 Trial for Sarcoma.
Hirakawa A; Nishikawa T; Yonemori K; Shibata T; Nakamura K; Ando M; Ueda T; Ozaki T; Tamura K; Kawai A; Fujiwara Y
Ther Innov Regul Sci; 2018 May; 52(3):334-338. PubMed ID: 29714533
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open-Label, Randomized, Bayesian Noninferiority Trial.
Brogan PA; Arch B; Hickey H; Anton J; Iglesias E; Baildam E; Mahmood K; Cleary G; Moraitis E; Papadopoulou C; Beresford MW; Riley P; Demir S; Ozen S; Culeddu G; Hughes DA; Dolezalova P; Hampson LV; Whitehead J; Jayne D; Ruperto N; Tudur-Smith C; Eleftheriou D
Arthritis Rheumatol; 2021 Sep; 73(9):1673-1682. PubMed ID: 33760371
[TBL] [Abstract][Full Text] [Related]
12. A pragmatic, adaptive clinical trial design for a rare disease: The FOcal Cerebral Arteriopathy Steroid (FOCAS) trial.
Park Y; Fullerton HJ; Elm JJ
Contemp Clin Trials; 2019 Nov; 86():105852. PubMed ID: 31614215
[TBL] [Abstract][Full Text] [Related]
13. Bayesian methods for pilot studies.
Willan AR; Thabane L
Clin Trials; 2020 Aug; 17(4):414-419. PubMed ID: 32297539
[TBL] [Abstract][Full Text] [Related]
14. Design and analysis features used in small population and rare disease trials: A targeted review.
Partington G; Cro S; Mason A; Phillips R; Cornelius V
J Clin Epidemiol; 2022 Apr; 144():93-101. PubMed ID: 34910979
[TBL] [Abstract][Full Text] [Related]
15. Sample size determination for Bayesian analysis of small n sequential, multiple assignment, randomized trials (snSMARTs) with three agents.
Wei B; Braun TM; Tamura RN; Kidwell K
J Biopharm Stat; 2020 Nov; 30(6):1109-1120. PubMed ID: 32892710
[TBL] [Abstract][Full Text] [Related]
16. Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study.
Brard C; Hampson LV; Gaspar N; Le Deley MC; Le Teuff G
BMC Med Res Methodol; 2019 Apr; 19(1):85. PubMed ID: 31018832
[TBL] [Abstract][Full Text] [Related]
17. Bayesian treatment comparison using parametric mixture priors computed from elicited histograms.
Thall PF; Ursino M; Baudouin V; Alberti C; Zohar S
Stat Methods Med Res; 2019 Feb; 28(2):404-418. PubMed ID: 28870123
[TBL] [Abstract][Full Text] [Related]
18. A Bayesian Sample Size Estimation Procedure Based on a B-Splines Semiparametric Elicitation Method.
Azzolina D; Berchialla P; Bressan S; Da Dalt L; Gregori D; Baldi I
Int J Environ Res Public Health; 2022 Oct; 19(21):. PubMed ID: 36361129
[TBL] [Abstract][Full Text] [Related]
19. Bayesian sample sizes for exploratory clinical trials comparing multiple experimental treatments with a control.
Whitehead J; Cleary F; Turner A
Stat Med; 2015 May; 34(12):2048-61. PubMed ID: 25765252
[TBL] [Abstract][Full Text] [Related]
20. Assurance calculations for planning clinical trials with time-to-event outcomes.
Ren S; Oakley JE
Stat Med; 2014 Jan; 33(1):31-45. PubMed ID: 23861270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
